Antengene Corporation Limited · HKEX:6996

Antengene — Investor Presentation (November 2021)

32 slides from Antengene's investor presentation, Nov 29, 2021

  1. Slide 1: Antengene Corporation Investor Presentation

    ANTENGENE CORPORATION (SEHK: 6996.HK) Treating Patients Beyond Borders INVESTOR PRESENTATION NOVEMBER 2021

  2. Slide 2: Disclaimer

    Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following: The information in this presentation has been prepared by representatives of Antengene Corporation Limited (the "Company" and, together with its subs

  3. Slide 3: Agenda

    AGENDA I. Overview II. XPO1 deep-dive III. Commercial readiness IV. Global assets V. Other clinical stage assets VI. Growth strategy

  4. Slide 4: I. Overview

    I. Overview

  5. Slide 5: Fully Integrated Asia Pacific Biopharma Focused on Global Oncology Drugs

    Fully Integrated Asia Pacific Biopharma Focused on Global First-in-Class / Best-in-Class Oncology Drugs Strong Clinical Commercial Scale Proven In-house Development and Manufacturing Commercialization Regulatory Track Facilities Capabilities • 8 internally developed assets Record • 3 INDs in 2021/ea

  6. Slide 6: Dual Engine of Growth Through Value-adding Partnerships and In-house Discovery

    Dual Engine of Growth Through Value-adding Partnerships and In-house Discovery 2021+ 2020 Hong Kong 2019 IPO 2017 2018 (Nov 2020) Approval(s) NDA Hong Kong Submissions Taiwan INDs* 3 INDs 6 INDs 11 INDs 19 INDs Partnerships APAC expansion Pipeline 9 assets (including 3 in- 12 assets (including 6 in-

  7. Slide 7: Targeting Multiple Signaling Pathways from Nucleus to Extracellular Microenvironment

    Targeting Multiple Signaling Pathways from Nucleus to Extracellular Microenvironment, Enabling Novel Combination Treatment Strategies Mechanism of Action of Antengene’s Pipeline Antengene’s Pipeline Tumor Microenvironment TME regulator: SINE T ATG-037 NK cell cell Macrophage regulator: ATG-032, ATG-

  8. Slide 8: A Near-to-mid Term Trial Program Expanding the Role of Lead Assets

    A Near-to-mid Term Trial Program Expanding the Role of Lead Assets Target Assets Regimen Pre-clinical Phase I Phase II Phase III NDA Commercialization Antengene Rights Partner (Modality) Combo with R/R Multiple Myeloma (MARCH) STORM (US and SK NDA approved) dexamethasone (dex) Combo with bortezomib

  9. Slide 9: An Early-stage In-house Pipeline with Transformational Potential

    An Early-stage In-house Pipeline with Transformational Potential Target Lead Antengene Assets Regimen Hits Discovery In vitro efficacy In vivo efficacy CMC/Tox IND Phase I Partner (Modality) Nomination Rights ATG-017 ERK1/2 Monotherapy R/R Hem/Onc (ERASER) (AZD-0364) (Small molecule) PD-L1/4-1BB ATG

  10. Slide 10: Advancing Clinical and Regulatory Development, with NDA Submissions in Multiple Markets

    Advancing Clinical and Regulatory Development, with NDA Submissions Completed or Undergoing in Multiple Markets Achieved Registrational Trials 2021 CSCO Guidelines inclusion of ATG- 19 5 Expanded Karyopharm in- licensing deal to include 17 010 (selinexor) of multiple treatment regimens IND approval

  11. Slide 11: II. XPO1 deep-dive

    II. XPO1 deep-dive

  12. Slide 12: ATG-010 (Selinexor) - First-in-class and Only-in-class SINE Compound

    ATG-010 (Selinexor) - First-in-class and Only-in-class SINE Compound with Unique MoA and Differentiated Profile China MM Market Size2 (US$ bn) 2019 2030 • First-in-class and only-in-class SINE compound Unique CAGR: 15.1% • Approved by U.S. FDA in 2L MM and 3L DLBCL 0.9 4.1 MoA • SVd/SPd/SDd/Sd/S inc

  13. Slide 13: Clinical Benefits of the SINE Class Validated in Multiple Myeloma and DLBCL

    Clinical Benefits of the SINE Class Validated by Selinexor’s Completed and Ongoing Studies in Multiple Myeloma and DLBCL FDA Approved FDA Approved FDA Approved BOSTON STOMP STORM SADAL (SVd) (SVd/SPd/SRd/SKd/etc.) (Sd) (S) • 1-3 prior therapies • 11 combinations • mOS (≥MR): 15.6 mos • 2-5 prior lin

  14. Slide 14: ATG-016 (Eltanexor) – 2nd Generation XPO1 Inhibitor

    ATG-016 (Eltanexor) – 2nd Generation XPO1 Inhibitor to Fortify Differentiated Market Leadership in Hematology and Solid Tumor Initial compelling efficacy and safety data ATG-016 (KPT-8602) Phase I/II Trial1 1 Evidenced in in HR-MDS through the KPT-8602 • n=15 patients evaluated for efficacy (median

  15. Slide 15: III. Commercialization Readiness

    III. Commercialization Readiness

  16. Slide 16: Antengene is Getting Ready for a First-in-class Launch in China and APAC

    Antengene is Getting Ready for a First-in-class Launch in China and APAC Antengene Expects to Launch XPOVIOTM (Selinexor) in China/APAC markets by the beginning of 2022 Pre-launch Activities Ongoing Established Team with Multiple Coupled with Strong Scientific Conducting Active Stakeholder Successfu

  17. Slide 17: Experience in Launching Top Hematology Products Globally, in APAC and China

    Experience in Launching Top Hematology Products Globally, in APAC and China Commercialization Strategy Commercialization in APAC Commercialization in China ◼ 30+ years of experience in ◼ 30+ years of experience in the ◼ 30+ years of experience in the pharmaceutical industry, pharmaceutical industry,

  18. Slide 18: IV. Global assets

    IV. Global assets

  19. Slide 19: ATG-017 - Potential Best-in-class ERK1/2 Inhibitor

    ATG-017 - Potential Best-in-class ERK1/2 Inhibitor Best-in-class potential • ATG-017 is a potent and selective small molecule extracellular signal-regulated kinases 1 and 2 (ERK1/2) inhibitor with best-in-class potential • No ERK1/2 inhibitors have been approved in China or worldwide; should maintai

  20. Slide 20: ATG-101 - Bispecific Antibody Targeting Both PD-L1 and 4-1BB

    ATG-101 - Bispecific Antibody Targeting Both PD-L1 and 4-1BB • ATG-101 is a bispecific antibody targeting both PD- Releasing the brakes L1 and 4-1BB with • Higher PDL1 binding affinity compared with 4- Complementary 1BB to allow the tumor specific localization mechanism of PD-L1/4-1BB MHC TCR • PD-L

  21. Slide 21: ATG-037 - an Orally Available, Small Molecule CD73 Inhibitor

    ATG-037 - an Orally Available, Small Molecule CD73 Inhibitor Teff NK Next generation IO & differentiation: • CD73 is the ecto-5‘-nucleotidase, catalyzing the conversion of AMP to adenosine, 1 a key immune suppressive molecule in the tumor microenvironment Adenosine inhibits the cytotoxic • Orally av

  22. Slide 22: ATG-018 - an Orally Available, Small Molecule ATR inhibitor

    ATG-018 - an Orally Available, Small Molecule ATR inhibitor • By targeting ATR, ATG-018 inhibits DNA damage repair, inducing tumor cell cycle arrest and tumor cell death DNA Damage ATG-018 ATR ATM • Pre-clinical: ATG-018 demonstrates superior in vivo efficacy compared with ATM/P53 clinical bench mar

  23. Slide 23: Antengene In-house Developed Novel Assets Target Key Oncogenic Pathways

    Antengene In-house Developed Novel Assets Target Key Oncogenic Pathways to Address Significant Unmet Medical Needs ATG-022 ATG-012 ATG-031 ATG-027 Target Claudin 18.2 KRAS G12C CD24 B7H3/PDL1 Indication Solid tumors Solid tumor Hematology / solid tumor Hematology / solid tumor Modality ADC Small mol

  24. Slide 24: V. Other clinical stage assets

    V. Other clinical stage assets

  25. Slide 25: ATG-008 (Onatasertib) - Potential First-in-class Dual mTORC1/2 Inhibitor

    ATG-008 (Onatasertib) - Potential First-in-class Dual mTORC1/2 Inhibitor ATG-008 clinical trial data Potentially a first-in-class, second-generation Meaningful efficacy in HBV+ HCC patients: mTOR inhibitor, which has advantages over first- ✓ Unconfirmed Best Overall Response Rate generation drugs by

  26. Slide 26: ATG-527 (Verdinexor) - XPO1 inhibitor for Indications beyond Oncology

    ATG-527 (Verdinexor) - XPO1 inhibitor for Indications beyond Oncology ATG-527 (verdinexor) is also an XPO1 inhibitor with broad and differentiated non-oncology indications: potentially be used to treat autoimmune and anti-infectious diseases Preclinical studies 1 Effective in reducing nephritis in t

  27. Slide 27: ATG-019 – Potential First-in-class PAK4/NAMPT Inhibitor

    ATG-019 – Potential First-in-class and Only-in-class PAK4/NAMPT Inhibitor Potential first-in-class, oral inhibitor Phase I clinical trial for evaluation of of p21-activated kinase 4 (PAK4) and ATG-019 its safety, tolerability and efficacy in nicotinamide phosphoribosyltransferase patients with advan

  28. Slide 28: VI. Growth Strategy

    VI. Growth Strategy

  29. Slide 29: Growth Strategies in Becoming a Global Leading Biopharma

    Growth Strategies in Becoming a Global Leading Biopharma Continue to carry out differentiated, efficient and effective clinical development strategies to drive accelerated regulatory pathway Further develop China and APAC commercial platform to solidify regional presence Expand in-house discovery an

  30. Slide 30: Q&A Thank You!

    Q&A Thank You! Antengene Corporation (SEHK: 6996.HK) Treating Patients Beyond Borders

  31. Slide 31: Exportin 1 and ATG-010 (Selinexor) Mechanism

    Exportin 1, a major nuclear exporter for tumor suppressor proteins and cell growth regulators; ATG-010 (Selinexor), an oral selective XPO1 inhibitor Exportin 1 (XPO1, CRM1) The major nuclear export protein for1,2,3: • Tumor suppressor proteins (e.g., p53, pRb, IkB, FOXO3a) • eIF4E-bound oncoprotein

  32. Slide 32: Multiple SINE Drug Candidates with Differentiated Profiles and Blockbuster Potentials

    Multiple SINE Drug Candidates with Differentiated Profiles and Blockbuster Potentials SINE portfolio is positioned to replicate success of other drug classes SINE Immunomodulatory (IMID) Proteasome Inhibitor (PI) Anti-CD38 $95 $5052 $1,074 $4,190 (Karyopharm / Antengene) (Celgene) (Millennium / Take

Antengene — Investor Presentation (November 2021) on 6ix